Mukai H - Search Results

1

[Genetic testing for effective Herceptin therapy].

Watanabe T, Katsumata N, Ando M, Mukai H, Shimizu C, Kitagawa R, Saijo NG. Watanabe T, et al. Among authors: mukai h. Nihon Rinsho. 2002 Mar;60(3):603-11. Nihon Rinsho. 2002. PMID: 11904980 Review. Japanese.

2

Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel.

Mukai H, Watanabe T, Ando M, Katsumata N. Mukai H, et al. Int J Clin Oncol. 2003 Feb;8(1):23-5. doi: 10.1007/s101470300002. Int J Clin Oncol. 2003. PMID: 12601538

3

Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan.

Kouno T, Katsumata N, Mukai H, Ando M, Watanabe T. Kouno T, et al. Among authors: mukai h. Jpn J Clin Oncol. 2003 Jun;33(6):309-13. doi: 10.1093/jjco/hyg062. Jpn J Clin Oncol. 2003. PMID: 12913086

4

[Treatment guidelines for systemic adjuvant therapy of breast cancer].

Watanabe T, Mukai H. Watanabe T, et al. Among authors: mukai h. Nihon Rinsho. 2006 Mar;64(3):419-23. Nihon Rinsho. 2006. PMID: 16529030 Japanese.

5

The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone.

Mizuno T, Katsumata N, Mukai H, Shimizu C, Ando M, Watanabe T. Mizuno T, et al. Among authors: mukai h. Support Care Cancer. 2007 Mar;15(3):287-91. doi: 10.1007/s00520-006-0126-6. Epub 2006 Aug 29. Support Care Cancer. 2007. PMID: 16941132

6

Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.

Kawada K, Murakami K, Sato T, Kojima Y, Ebi H, Mukai H, Tahara M, Shimokata K, Minami H. Kawada K, et al. Among authors: mukai h. Jpn J Clin Oncol. 2007 Jan;37(1):44-8. doi: 10.1093/jjco/hyl116. Epub 2006 Oct 23. Jpn J Clin Oncol. 2007. PMID: 17060407 Clinical Trial.

7

An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients.

Mukai H, Watanabe T, Ando M, Katsumata N. Mukai H, et al. Jpn J Clin Oncol. 2006 Dec;36(12):808-10. doi: 10.1093/jjco/hyl108. Epub 2006 Nov 14. Jpn J Clin Oncol. 2006. PMID: 17105737

8

[Management of toxicity associated with chemotherapy for breast cancer].

Mukohara T, Mukai H. Mukohara T, et al. Among authors: mukai h. Nihon Rinsho. 2007 Jun 28;65 Suppl 6:516-22. Nihon Rinsho. 2007. PMID: 17682204 Review. Japanese. No abstract available.

9

Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed.

Mukai H, Watanabe T, Ando M, Shimizu C, Katsumata N. Mukai H, et al. Breast Cancer Res Treat. 2009 Jan;113(1):123-8. doi: 10.1007/s10549-007-9889-9. Epub 2008 Jan 10. Breast Cancer Res Treat. 2009. PMID: 18193480

10

Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer.

Mukai H, Katsumata N, Ando M, Watanabe T. Mukai H, et al. Am J Clin Oncol. 2010 Feb;33(1):32-5. doi: 10.1097/COC.0b013e31819ccc55. Am J Clin Oncol. 2010. PMID: 19786850 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

845 results

Search Page

Filters